NK cell therapy

Natural killer cells (NK cells) are a unique type of lymphocyte in the innate immune system capable of recognizing and destroying cells that have altered their phenotype, such as those infected with viruses, tumor cells, or those that have undergone genetic mutations. Unlike T cells, NK cells do not require prior antigen sensitization and act instantly, relying on the balance of activating and inhibitory signals transmitted through their receptors.

The key activating receptors of NK cells are NKG2D, NKp30, NKp44, and NKp46 , which recognize stress-induced molecules on the surface of atypical cells. Upon activation, NK cells release perforin and granzymes , inducing target apoptosis, and also produce cytokines ( IFN-γ, TNF-α ) that modulate the adaptive immune response.

Modern oncology is increasingly turning to the body’s natural defense mechanisms. One of the most promising areas of immune therapy is NK cells (Natural Killer cells) —lymphocytes of the innate immune system that have the ability to recognize and destroy abnormal cells without prior sensitization.
These cells act as a “first line of defense,” instantly responding to threats such as viral infection, cell transformation into a tumor, or genetic disruption.

NK cell biology

NK cells comprise 5–15% of all circulating lymphocytes. Their unique ability to distinguish between normal and abnormal cells without the involvement of antibodies or antigen-specific receptors is key .
Their mechanism of action is based on the balance between activating (NKG2D, NKp30, NKp44, NKp46) and inhibitory (KIR, NKG2A) receptors.
When a danger signal exceeds an inhibitory threshold, the NK cell initiates a killing cascade: it releases perforin and granzymes , which induce apoptosis of the target cell.

In addition to the direct cytotoxic effect, NK cells secrete cytokines ( interferon-γ, TNF-α ), which activate macrophages, T-lymphocytes and enhance the antitumor immune response.

Modern directions of therapy

Developing methods to activate and enhance NK cells is currently a key area of ​​cell therapy.
Promising approaches include:

• Ex vivo expansion of autologous or donor NK cells followed by reinfusion into the patient.
• The use of cytokines IL-2, IL-15, IL-21 , stimulating the proliferation and survival of NK cells.
• Combination protocols with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1) that eliminate receptor blockade.
• CAR-NK therapy – genetically modified NK cells carrying chimeric antigen receptors against specific tumor targets (EGFRvIII, HER2, etc.).

Of particular interest are protocols in which NK cells are combined with other biomodulators , such as GcMAF, thymosin alpha-1, peptides and exosomes , which help restore immune surveillance and normalize intercellular signals.

The future of cell therapy in oncology lies in the integration of innate and adaptive immune technologies .
NK cells, with their rapid action, safety, and versatility, are becoming a key tool in personalized medicine.
Combined with molecular diagnostics, peptide regulation, and quantum regeneration technologies, they pave the way to a new treatment paradigm —restoring the body’s natural ability to recognize and eliminate tumors.

NK cells are not just an element of the immune system, but a strategic resource for future medicine. Their activation and careful inclusion in therapeutic protocols can transform even aggressive diseases such as glioblastoma from a fatal diagnosis into a manageable condition.

NK therapy is a gentle, physiological method for restoring natural immune surveillance , suitable for both the prevention and treatment of complex immune-related diseases and oncological diseases.
Combined with peptide, exosome, and antioxidant therapies, it forms a new area of ​​personalized medicine, shifting the focus from fighting disease to maintaining the body’s internal strength and immune balance .

What is the procedure?

Natural Killer cell therapy (NK therapy) is a cellular immunotherapy method aimed at enhancing the innate immune response by administering activated NK cells to the patient. These cells can be:

• autologous – isolated from the patient’s own blood,
• allogeneic – obtained from a compatible donor (a healthy relative or a certified donor).

The procedure is carried out in sterile conditions under the supervision of an immunologist and cellular biotechnologist.

Stages of implementation

1. Blood sampling (or leukopheresis) – mononuclear cells are isolated from peripheral blood.
2. Isolation and expansion of the NK fraction – in laboratory conditions, cells are cultured for 10-14 days in the presence of cytokines ( IL-2, IL-15, IL-21 ) and growth factors to increase their quantity and activation.
3. Quality control – before administration, the culture purity, activation level (CD16⁺/CD56⁺), and absence of bacterial or viral contamination are checked.
4. NK cell infusion is administered intravenously over 30–60 minutes. The number of cells administered depends on the target (usually 1–5 × 10⁹ activated cells).
5. Post-procedure observation : the patient remains under the doctor’s supervision for 30–60 minutes; complications are extremely rare.

For preventive purposes, the procedure is carried out in a course of 1 to 3 infusions with an interval of 2–4 weeks ; for treatment programs, 6–8 sessions with monitoring of the immune status.

Preventive use

Even in healthy individuals, NK cell activity declines with age, increasing the risk of chronic infections, tumor transformation, and chronic fatigue syndromes.
Prophylactic NK cell therapy is indicated for:

• restoration of immune balance after viral diseases;
• prevention of oncological processes in individuals with a burdened heredity;
• increasing overall stress resistance and adaptation of the body;
• support in anti-aging and cellular rejuvenation programs;
• accelerating recovery after intense exercise, injuries or surgeries;
• comprehensive detoxification and rehabilitation after chemotherapy and radiotherapy.

Main indications

• malignant neoplasms (including glioblastoma, liver cancer, lung cancer, stomach cancer, breast cancer);
• chronic viral infections (cytomegalovirus, Epstein-Barr virus, herpes, hepatitis B and C, papillomavirus);
• immunodeficiency states, chronic fatigue syndrome;
• autoimmune diseases (in complex therapy under the supervision of a specialist);
• prevention of relapse after successful tumor treatment;
• age-associated disorders, decreased vital energy and immune activity.

Contraindications

• acute infectious processes (viral, bacterial, fungal);
• active autoimmune diseases in the acute phase;
• severe forms of anemia and thrombocytopenia;
• decompensated diseases of the heart, liver or kidneys;
• pregnancy and lactation;
• individual hypersensitivity to components of the culture medium (rare).

Before the course, a complete examination is required: general blood test, biochemistry, coagulogram, viral markers, immunogram.

Expected effects

• normalization of immune activity and cytokine levels;
• reduction of chronic inflammatory processes;
• improved overall well-being, sleep and energy;
• increasing resistance to infections and stress;
• slowing down age-related changes and improving tissue regeneration.

The effect appears gradually, reaching its peak 2–4 weeks after the course.

Safety and tolerability

The procedure is well tolerated, does not require hospitalization, and does not cause immune conflicts, as it uses the patient’s own (autologous) or compatible (allogeneic) cell material.
Mild reactions, such as low-grade fever, fatigue, and redness along the vein, are rare, as a result of the activation of the immune response.

At ANS Clinic , we use future technologies today:
cellular therapies, NK cells, peptides, exosomes, quantum baths, and photonic rejuvenation.
Consult with an expert physician to create a personalized plan for cellular restoration and immune regulation .

🔬 Diagnostics • Therapy • Recovery
📍 Marbella | Boris Hospital SL
📞 Appointments: +34 660 733 093